Pharmamarketeer

EMA validates Gilead’s MAA for lenacapavir to treat HIV─1 in people with limited therapy options

EMA

Gilead Sciences announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, an investigational, long─acting HIV─1 capsid inhibitor, has been fully validated and is now under evaluation with

Advertentie(s)